Back to Newsroom
Back to Newsroom

RDInvesting Provides Investors with Free In-Depth Equity Reports on ARMH, AVA, KLAC and LMNS

Wednesday, 09 April 2014 08:40 AM

Topic:

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.

ARM Holdings plc (NASDAQ: ARMH) shares increased 4.35 percent to close at $50.40 a share Tuesday. The stock traded between $48.71 and $50.44 on volume of 1.77 million shares traded. Analysts at Bernstein Research have recently upgraded the company’s rating to "market perform" from "underperform". Shares of ARM Holdings have fallen approximately 8.0 percent year-to-date.

Find out more about ARM Holdings including full access to the free equity report at:     
www.RDInvesting.com/ARMH

Avista Corp. (NYSE: AVA) shares increased 1.78 percent to close at $30.86 a share Tuesday. The stock traded between $30.02 and $30.94 on volume of 663,694 shares traded. Analysts at CRT Capital have recently initiated coverage on the company with a "fair value" rating and a price target of $32.00. Shares of Avista have gained approximately 10.0 percent year-to-date.

Find out more about Avista including full access to the free equity report at:      
www.RDInvesting.com/AVA

KLA-Tencor Corporation (NASDAQ: KLAC) shares declined 1.13 percent to close at $68.03 a share Tuesday. The stock traded between $67.61 and $68.53 on volume of 1.71 million shares traded. Analysts at Pacific Crest have recently downgraded the company’s rating to "sector perform" from "outperform". Shares of KLA-Tencor have gained approximately 5.0 percent year-to-date.

Find out more about KLA-Tencor including full access to the free equity report at:       
www.RDInvesting.com/KLAC

Lumenis Ltd. (NASDAQ: LMNS) shares declined 0.60 to close at $9.90 a share Tuesday. The stock traded between $9.84 and $10.47 on volume of 700,237 shares traded. Analysts at Credit Suisse have recently initiated coverage on the company with an "outperform" rating and a price target of $14.00. Shares of Lumenis have fallen approximately 18.0 percent year-to-date.

Find out more about Lumenis including full access to the free equity report at:        
www.RDInvesting.com/LMNS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:           
Research Driven Investing            
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: